Literature DB >> 15793140

Novel TEM-type extended-spectrum beta-lactamase, TEM-134, in a Citrobacter koseri clinical isolate.

Mariagrazia Perilli1, Claudia Mugnaioli, Francesco Luzzaro, Marianna Fiore, Stefania Stefani, Gian Maria Rossolini, Gianfranco Amicosante.   

Abstract

A new natural TEM derivative with extended-spectrum beta-lactamase activity, TEM-134, was identified in a ceftazidime-resistant clinical isolate of Citrobacter koseri. Compared to TEM-1, TEM-134 contains the following mutations: Q39K, E104K, R164H, and G238S. The bla(TEM-134) gene was not transferable by conjugation and, apparently, was chromosomally encoded. Expression studies with Escherichia coli revealed efficient cefotaximase and ceftazidimase activity for TEM-134.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793140      PMCID: PMC1068604          DOI: 10.1128/AAC.49.4.1564-1566.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes.

Authors:  R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

3.  The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics.

Authors:  C Cantu; T Palzkill
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

4.  A natural polymorphism in beta-lactamase is a global suppressor.

Authors:  W Huang; T Palzkill
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 5.  Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure.

Authors:  J R Knox
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

6.  Hybridization of nucleic acids directly in agarose gels.

Authors:  S G Tsao; C F Brunk; R E Pearlman
Journal:  Anal Biochem       Date:  1983-06       Impact factor: 3.365

7.  Multiplicity of TEM-derived beta-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids.

Authors:  C M Chanal; D L Sirot; A Petit; R Labia; A Morand; J L Sirot; R A Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases.

Authors:  David L Paterson; Kristine M Hujer; Andrea M Hujer; Bethany Yeiser; Michael D Bonomo; Louis B Rice; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy.

Authors:  Laura Pagani; Elisabetta Mantengoli; Roberta Migliavacca; Elisabetta Nucleo; Simona Pollini; Melissa Spalla; Rossana Daturi; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Citrobacter diversus ULA27 produces two forms of a chromosomal beta-lactamase.

Authors:  B Oliva; M C Marinucci; G Amicosante; A Oratore; P M Bennett
Journal:  J Antimicrob Chemother       Date:  1987-07       Impact factor: 5.790

View more
  2 in total

1.  Infective endocarditis due to Citrobacter koseri in an immunocompetent adult.

Authors:  A Dzeing-Ella; T A Szwebel; J Loubinoux; S Coignard; A Bouvet; C Le Jeunne; E Aslangul
Journal:  J Clin Microbiol       Date:  2009-10-07       Impact factor: 5.948

2.  Evolving Bacterial Fitness with an Expanded Genetic Code.

Authors:  Drew S Tack; Austin C Cole; Raghav Shroff; Barrett R Morrow; Andrew D Ellington
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.